hVIVO plc (FRA:CRO)

Germany flag Germany · Delayed Price · Currency is EUR
0.1170
+0.0010 (0.86%)
At close: Jun 27, 2025, 10:00 PM CET
-61.76%
Market Cap 82.57M
Revenue (ttm) 80.07M
Net Income (ttm) 12.88M
Shares Out n/a
EPS (ttm) 0.02
PE Ratio 6.41
Forward PE n/a
Dividend 0.00 (2.05%)
Ex-Dividend Date May 15, 2025
Volume 2,500
Average Volume 1,118
Open 0.1170
Previous Close 0.1160
Day's Range 0.1170 - 0.1170
52-Week Range 0.0835 - 0.3660
Beta n/a
RSI 45.69
Earnings Date Sep 10, 2025

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and C... [Read more]

Industry Commercial Physical and Biological Research
CEO Yamin Khan
Employees 301
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol CRO
Full Company Profile

Financial Performance

In 2024, hVIVO's revenue was 66.22 million, an increase of 12.87% compared to the previous year's 58.67 million. Earnings were 10.65 million, a decrease of -33.90%.

Financial numbers in GBP Financial Statements

News

There is no news available yet.